Retroperitoneal fibrosis treated with methylprednisolon pulse and disease-modifying antirheumatic drugs

Scand J Urol Nephrol. 1994 Sep;28(3):237-42.

Abstract

The conventional treatment of patients with ureteric obstruction due to retroperitoneal fibrosis (RF) is surgery in combination with long-term corticosteroids. This report describes 11 cases of RF with ureteric obstruction treated with methyl-prednisolon pulse therapy (MPPT) in combination with azathioprine or penicillamine following initial insertion of ureteral stents. The medial treatment suggested was successful in 7 patients, but only moderately effective in the last 4 patients. This principle of non-operative management of RF has not been previously reported.

MeSH terms

  • Adult
  • Azathioprine / administration & dosage
  • Azathioprine / therapeutic use*
  • Combined Modality Therapy
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Methylprednisolone / administration & dosage
  • Methylprednisolone / therapeutic use*
  • Nephrostomy, Percutaneous
  • Penicillamine / administration & dosage
  • Penicillamine / therapeutic use*
  • Radiography
  • Retroperitoneal Fibrosis / complications
  • Retroperitoneal Fibrosis / diagnostic imaging
  • Retroperitoneal Fibrosis / drug therapy*
  • Stents
  • Time Factors
  • Treatment Outcome
  • Ureteral Obstruction / etiology
  • Ureteral Obstruction / therapy

Substances

  • Penicillamine
  • Azathioprine
  • Methylprednisolone